SELF-CERV Pivotal Study: SELF-Collection for CERVical Cancer Screening
- Conditions
- HPV 16 InfectionHPV InfectionHigh Risk HPVHpv
- Interventions
- Device: Teal Wand Self-Collection Device Group
- Registration Number
- NCT06120205
- Lead Sponsor
- Teal Health, Inc.
- Brief Summary
The goal of this method comparison study is to compare the detection of hrHPV collected using the Teal Wand Self-Collection device to hrHPV detected from HCP (health care provider) cervical collection using primary HPV testing assays.
Participants will be asked to use the Teal Wand to provide a self-collected sample prior to a healthcare provider collected sample to be tested for hrHPV. Secondary measure will include usability and preferences.
- Detailed Description
To demonstrate that participants who are representative of the intended use population can understand the Instructions for Use (IFU) and appropriately use the Teal self-collection device to collect adequate vaginal cells/material for use in primary hrHPV screening (primary outcome).
To produce sufficient primary hrHPV test results following self-collection, as compared to the current SoC method of HCP specimen collection, when paired samples are tested using FDA approved primary hrHPV assays (Roche cobas and/or BD OnClarity).
Primary Effectiveness Objective
⢠To evaluate the performance of a self-collect device for hrHPV detection as compared to standard of care (SoC) by:
* Agreement of hrHPV self-collected sample(s) as compared to HCP-collected sample results.
* Calculating the invalid rate of tested samples.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- Female
- Target Recruitment
- 870
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Self-Collection / Clinician Collection Teal Wand Self-Collection Device Group Patient serves as own comparator/control in this method comparison study where the investigational intervention is use of the self-collect device and the comparator is the standard of care clinician collection.
- Primary Outcome Measures
Name Time Method Safety: SAE rate 6-14 days following collections SAE rate is equivalent for both self-collect and clinician collect interventions
Efficacy: Detection of hrHPV in self-collect and clinician collect samples Samples tested within 7 days of collection PPA/NPA (Positive Percent Agreement)/(Negative Percent Agreement) of hrHPV detection of self-collected and clinician collected samples
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (15)
Birmingham OBGYN / Alabama Clinical Therapeutics
đşđ¸Birmingham, Alabama, United States
Planned Parenthood Northern California
đşđ¸San Francisco, California, United States
University of Colorado Anschutz Medical Campus
đşđ¸Aurora, Colorado, United States
Planned Parenthood Southern New England
đşđ¸New Haven, Connecticut, United States
Yale University
đşđ¸New Haven, Connecticut, United States
Woman's Hospital
đşđ¸Baton Rouge, Louisiana, United States
Johns Hopkins University
đşđ¸Baltimore, Maryland, United States
Planned Parenthood League of Massachusetts
đşđ¸Boston, Massachusetts, United States
Planned Parenthood St. Louis Region
đşđ¸Saint Louis, Missouri, United States
Washington University
đşđ¸Saint Louis, Missouri, United States
New York University Langone Hospital
đşđ¸Mineola, New York, United States
Unified Women's Clinical Research Raleigh
đşđ¸Raleigh, North Carolina, United States
Unified Women's Clinical Research - Lyndhurst
đşđ¸Winston-Salem, North Carolina, United States
Planned Parenthood Gulf Coast
đşđ¸Houston, Texas, United States
University of Wisconsin - Madison
đşđ¸Madison, Wisconsin, United States